# A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

> **NCT05332366** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 35 (actual)

## Conditions studied

- Frontal Fibrosing Alopecia

## Interventions

- **DRUG:** Delgocitinib cream
- **DRUG:** Delgocitinib cream vehicle

## Key facts

- **NCT ID:** NCT05332366
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-19
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-05-22
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332366, "A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05332366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*